Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine
This study showed that the candidate vaccine is safe and elicits an antigen-dose-dependent serum antibody response. In summary, we determined the optimum antigen dose in a Kazfluvac® adjuvant formulation required for induction of heightened immunogenicity and protective efficacy to mitigate H5N1 disease in experimental animals, suggesting its readiness for clinical studies in humans.
Source: Archives of Virology - Category: Virology Source Type: research
More News: Bird Flu | Bird Flu (H5N1 Avian Influenza) Vaccine | Flu Pandemic | H5N1 | Influenza | Influenza Vaccine | Laboratory Medicine | Pandemics | Study | Vaccines | Veterinary Vaccinations | Virology